drugset
drugset / Trial / NCT00816361

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

NCT00816361 ↗

Phase 1 Completed 43 enrolled MedImmune LLC
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.

Timeline

Start
2009-03-09
Primary completion
2012-09-11
Completion
2012-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject DUSIGITUMAB Monoclonal antibody 0.5 mg/kg Intravenous
Subject DUSIGITUMAB Monoclonal antibody 1.5 mg/kg Intravenous
Subject DUSIGITUMAB Monoclonal antibody 5 mg/kg Intravenous
Subject DUSIGITUMAB Monoclonal antibody 10 mg/kg Intravenous
Subject DUSIGITUMAB Monoclonal antibody 15 mg/kg Intravenous
Subject DUSIGITUMAB Monoclonal antibody 30 mg/kg Intravenous
Subject DUSIGITUMAB Monoclonal antibody 45 mg/kg Intravenous

Indications

cancer